Literature DB >> 14764277

The role of advanced glycation end products in the development of atherosclerosis.

Melpomeni Peppa1, Jaime Uribarri, Helen Vlassara.   

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Atherosclerosis constitutes the main pattern of cardiovascular disease and leads to thickening of the intima with plaque formation and eventual occlusion of the arterial lumen. A large amount of evidence links advanced glycation end products (AGEs) with the development or progression of atherosclerosis, regardless of the diabetic status. AGEs are a heterogenous group of compounds formed by the nonenzymatic reaction of reducing sugars with proteins, lipids, and nucleic acids. Although AGEs are formed endogenously in the body, diet has recently been recognized as an important exogenous source. An increased understanding of the mechanisms of formation and interaction of AGEs has allowed the development of several potential anti-AGE approaches.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764277     DOI: 10.1007/s11892-004-0008-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  54 in total

1.  Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs.

Authors:  A W Stitt; C He; S Friedman; L Scher; P Rossi; L Ong; H Founds; Y M Li; R Bucala; H Vlassara
Journal:  Mol Med       Date:  1997-09       Impact factor: 6.354

2.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

3.  Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.

Authors:  J R Rumble; M E Cooper; T Soulis; A Cox; L Wu; S Youssef; M Jasik; G Jerums; R E Gilbert
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.

Authors:  Helen Vlassara; Weijing Cai; Jill Crandall; Teresia Goldberg; Robert Oberstein; Veronique Dardaine; Melpomeni Peppa; Elliot J Rayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

5.  Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Authors:  H Vlassara; H Fuh; T Donnelly; M Cybulsky
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

6.  Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice.

Authors:  Reigh-Yi Lin; Ernane D Reis; Anthony T Dore; Min Lu; Newsha Ghodsi; John T Fallon; Edward A Fisher; Helen Vlassara
Journal:  Atherosclerosis       Date:  2002-08       Impact factor: 5.162

7.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.

Authors:  H Vlassara; H Fuh; Z Makita; S Krungkrai; A Cerami; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse.

Authors:  Susanna M Hofmann; Heng-Jiang Dong; Zhu Li; Weijing Cai; Jennifer Altomonte; Swan N Thung; Feng Zeng; Edward A Fisher; Helen Vlassara
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

9.  Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor.

Authors:  R Bucala; R Mitchell; K Arnold; T Innerarity; H Vlassara; A Cerami
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

10.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.

Authors:  W Palinski; T Koschinsky; S W Butler; E Miller; H Vlassara; A Cerami; J L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

View more
  18 in total

1.  Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats.

Authors:  Hongfeng Wang; Dorothee Weihrauch; Judy R Kersten; Jeffrey M Toth; Anthony G Passerini; Anita Rajamani; Sonja Schrepfer; John F LaDisa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

Review 2.  Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-07-31       Impact factor: 3.396

3.  Metabolic syndrome is associated with learning and recall impairment in middle age.

Authors:  Jason J Hassenstab; Victoria Sweat; Hannah Bruehl; Antonio Convit
Journal:  Dement Geriatr Cogn Disord       Date:  2010-04-24       Impact factor: 2.959

4.  Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract.

Authors:  Zehra Hashim; Shamshad Zarina
Journal:  Age (Dordr)       Date:  2010-09-15

5.  Secondary hyperparathyroidism and target organs in chronic kidney disease.

Authors:  M Nikodimopoulou; S Liakos
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

Review 6.  Advanced Glycation End Products: key player of the pathogenesis of atherosclerosis.

Authors:  Sanjiv Singh; Boddu Veerabadra Siva; V Ravichandiran
Journal:  Glycoconj J       Date:  2022-05-17       Impact factor: 3.009

7.  High serum level of methylglyoxal-derived AGE, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine, independently relates to renal dysfunction.

Authors:  Kenji Ito; Noriyuki Sakata; Ryoji Nagai; Jun-Ichi Shirakawa; Maho Watanabe; Ayako Mimata; Yasuhiro Abe; Tetsuhiko Yasuno; Yoshie Sasatomi; Katsuhisa Miyake; Naoko Ueki; Aki Hamauchi; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2016-06-25       Impact factor: 2.801

Review 8.  Low-calorie sweetener use and energy balance: Results from experimental studies in animals, and large-scale prospective studies in humans.

Authors:  Sharon P G Fowler
Journal:  Physiol Behav       Date:  2016-04-26

9.  Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications.

Authors:  Anjuman Gul; M Ataur Rahman; Asmat Salim; Shabana U Simjee
Journal:  Age (Dordr)       Date:  2008-09-03

10.  DL-3-n-butylphthalide protects endothelial cells against advanced glycation end product-induced injury by attenuating oxidative stress and inflammation responses.

Authors:  Chang-Yun Liu; Zhen-Hua Zhao; Zhi-Ting Chen; Chun-Hui Che; Zhang-Yu Zou; Xiao-Min Wu; Sheng-Gen Chen; Yuan-Xiao Li; Han-Bin Lin; Xiao-Fan Wei; Jie You; Hua-Pin Huang
Journal:  Exp Ther Med       Date:  2017-07-12       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.